Scientists Finally Crack an “Undruggable” Pancreatic Cancer Target and Nearly Double Survival

Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival

For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic tumors—something many scientists once thought couldn't be done. In a major clinical trial, the treatment nearly doubled survival for patients with advanced disease and reduced the risk of death by 60%.

New Pill for Pancreatic Cancer Also Fights Lung Cancer

A drug that just won FDA approval for pancreatic cancer may have a second act in the most common form of lung cancer. Daraxonrasib, made by Revolution Medicines, zeroes in on a KRAS gene mutation long thought impossible to target—and seen in roughly 30% of non-small-cell lung cancers, including...

New pancreatic cancer drug gives South Portland man hope for longer life

Eugene Slobodzian has been taking daraxonrasib since July as part of an expanded access trial. Last week, the FDA approved it for wide use, potentially doubling patients' life expectancy to 13 months.